| A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients B Oran, M de Lima, G Garcia-Manero, PF Thall, R Lin, U Popat, AM Alousi, ... Blood advances 4 (21), 5580-5588, 2020 | 145 | 2020 |
| Bayesian optimal interval design for dose finding in drug-combination trials R Lin, G Yin Statistical methods in medical research 26 (5), 2155-2167, 2017 | 91 | 2017 |
| Time-to-event Bayesian optimal interval design to accelerate phase I trials Y Yuan, R Lin, D Li, L Nie, KE Warren Clinical Cancer Research 24 (20), 4921-4930, 2018 | 88 | 2018 |
| BOIN12: Bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies R Lin, Y Zhou, F Yan, D Li, Y Yuan JCO precision oncology 4, 1393-1402, 2020 | 78 | 2020 |
| Inter-ethnic/racial facial variations: a systematic review and Bayesian meta-analysis of photogrammetric studies YF Wen, HM Wong, R Lin, G Yin, C McGrath PloS one 10 (8), e0134525, 2015 | 73 | 2015 |
| Time-to-event model-assisted designs for dose-finding trials with delayed toxicity R Lin, Y Yuan Biostatistics 21 (4), 807-824, 2020 | 57 | 2020 |
| STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials R Lin, G Yin Statistics in medicine 36 (26), 4106-4120, 2017 | 54 | 2017 |
| Maintenance with 5-azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients B Oran, M de Lima, G Garcia-Manero, PF Thall, R Lin, AM Alousi, ... Blood 132, 971, 2018 | 36 | 2018 |
| Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation A Olson, R Lin, D Marin, H Rafei, MH Bdaiwi, PF Thall, R Basar, ... Journal of Clinical Oncology, 0:0, 2021 | 33 | 2021 |
| The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990–2019: a population-based study YF Wen, MX Chen, G Yin, R Lin, YJ Zhong, QQ Dong, HM Wong Journal of Hematology & Oncology 14 (1), 89, 2021 | 30 | 2021 |
| Trends and patterns of disparities in burden of lung cancer in the United States, 1974-2015 YJ Zhong, YF Wen, HM Wong, G Yin, R Lin, SY Yang Frontiers in Oncology 9, 404, 2019 | 27 | 2019 |
| Nonparametric overdose control with late-onset toxicity in phase I clinical trials R Lin, G Yin Biostatistics 18 (1), 180-194, 2017 | 27 | 2017 |
| Keyboard design for phase I drug-combination trials H Pan, R Lin, Y Zhou, Y Yuan Contemporary clinical trials 92, 105972, 2020 | 26 | 2020 |
| TITE‐BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late‐onset toxicity and efficacy Y Zhou, R Lin, JJ Lee, D Li, L Wang, R Li, Y Yuan Statistics in medicine 41 (11), 1918-1931, 2022 | 24 | 2022 |
| Bayes factor and posterior probability: complementary statistical evidence to p-value R Lin, G Yin Contemporary clinical trials 44, 33-35, 2015 | 24 | 2015 |
| Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results IC Glitza Oliva, SD Ferguson, R Bassett Jr, AP Foster, I John, ... Nature medicine 29 (4), 898-905, 2023 | 20 | 2023 |
| Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials D Chihara, R Lin, CR Flowers, SR Finnigan, LM Cordes, Y Fukuda, ... The Lancet 400 (10351), 512-521, 2022 | 18 | 2022 |
| TOP: Time-to-event Bayesian optimal phase II trial design for cancer immunotherapy R Lin, RL Coleman, Y Yuan JNCI: Journal of the National Cancer Institute 112 (1), 38-45, 2020 | 18 | 2020 |
| An adaptive trial design to optimize dose-schedule regimes with delayed outcomes R Lin, PF Thall, Y Yuan Biometrics 76 (1), 304-315, 2020 | 17 | 2020 |
| Comments on ‘Competing designs for drug combination in phase I dose‐finding clinical trials’ by M‐K. Riviere, F. Dubois, and S. Zohar G Yin, R Lin Statistics in Medicine 34 (1), 13-17, 2015 | 15 | 2015 |
Guosheng YinUniversity of Hong KongDirección de correo verificada de hku.hk
